Zika virus pathogenesis and current therapeutic advances
- PMID: 33191867
- PMCID: PMC7850325
- DOI: 10.1080/20477724.2020.1845005
Zika virus pathogenesis and current therapeutic advances
Abstract
Zika virus (ZIKV) is an emerging arthropod-borne flavivirus that, upon infection, results in teratogenic effects and neurological disorders. ZIKV infections pose serious global public health concerns, prompting scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elaborated. Currently, no specific vaccines or drugs have been approved for ZIKV; however, some are undergoing clinical trials. Notably, several strategies have been used to develop antivirals, including drugs that target viral and host proteins. Additionally, drug repurposing is preferred since it is less costly and takes less time than other strategies because the drugs used have already been approved for human use. Likewise, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, peptide, protein, viral vectors, virus-like particles (VLPSs), inactivated-virus, and live-attenuated virus vaccines. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA both in vitro and in vivo. Importantly, most of these vaccines have entered clinical trials. Understanding the viral disease mechanism will provide better strategies for developing therapeutic agents against ZIKV. This review provides a comprehensive summary of the viral pathogenesis of ZIKV and current advancements in the development of vaccines and drugs against this virus.
Keywords: Antivirals; pathogenesis; sfRNAs; therapeutics; vaccines; zika virus.
Conflict of interest statement
No potential conflict of interest was reported by the authors.
Figures



Similar articles
-
Current Advances in Zika Vaccine Development.Vaccines (Basel). 2022 Oct 28;10(11):1816. doi: 10.3390/vaccines10111816. Vaccines (Basel). 2022. PMID: 36366325 Free PMC article. Review.
-
Strategies for Zika drug discovery.Curr Opin Virol. 2019 Apr;35:19-26. doi: 10.1016/j.coviro.2019.01.005. Epub 2019 Mar 7. Curr Opin Virol. 2019. PMID: 30852345 Review.
-
Zika Virus Subgenomic Flavivirus RNA Generation Requires Cooperativity between Duplicated RNA Structures That Are Essential for Productive Infection in Human Cells.J Virol. 2020 Aug 31;94(18):e00343-20. doi: 10.1128/JVI.00343-20. Print 2020 Aug 31. J Virol. 2020. PMID: 32581095 Free PMC article.
-
Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics.Viruses. 2017 Jun 13;9(6):143. doi: 10.3390/v9060143. Viruses. 2017. PMID: 28608813 Free PMC article. Review.
-
Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection.Front Med. 2021 Jun;15(3):404-415. doi: 10.1007/s11684-021-0834-9. Epub 2020 Dec 28. Front Med. 2021. PMID: 33369711 Free PMC article. Review.
Cited by
-
The Role of Epigallocatechin Gallate (EGCG) in Treatment and Management of Sexually Transmitted Viral Infections.Infect Disord Drug Targets. 2025;25(4):e18715265319110. doi: 10.2174/0118715265319110240916061200. Infect Disord Drug Targets. 2025. PMID: 39482915 Review.
-
Zika virus tropism and pathogenesis: understanding clinical impacts and transmission dynamics.Virol J. 2024 Oct 29;21(1):271. doi: 10.1186/s12985-024-02547-z. Virol J. 2024. PMID: 39472938 Free PMC article. Review.
-
Synthesis of copaiba (Copaifera officinalis) oil nanoemulsion and the potential against Zika virus: An in vitro study.PLoS One. 2023 Sep 7;18(9):e0283817. doi: 10.1371/journal.pone.0283817. eCollection 2023. PLoS One. 2023. PMID: 37676868 Free PMC article.
-
Investigation of the activity of baicalein towards Zika virus.BMC Complement Med Ther. 2023 May 3;23(1):143. doi: 10.1186/s12906-023-03971-4. BMC Complement Med Ther. 2023. PMID: 37138273 Free PMC article.
-
Development of an Eco-Friendly Nanogel Incorporating Pectis brevipedunculata Essential Oil as a Larvicidal Agent Against Aedes aegypti.Pharmaceutics. 2024 Oct 18;16(10):1337. doi: 10.3390/pharmaceutics16101337. Pharmaceutics. 2024. PMID: 39458666 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical